- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03095872
Comparison of the Effect of Vaseline and Bepanthen® "Wund- Und Heilsalbe" on the Wound Healing Following Laser Therapy (CO2)
Comparison of the Effect of Vaseline and Bepanthen® "Wund- Und Heilsalbe" on the Wound Healing Following Fractional Ablative Laser Treatment of Photo-damaged Skin
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The healing process and therefore the success of a laser treatment are strongly determined by an appropriate treatment with special skin care products of the laser-treated skin. Cooling measures prevent the swelling of the treated skin area, if applied directly after the procedure. A soothing and wound-healing-promoting care applied subsequently for seven days, can support and also speed up the healing process.
The Lumenis® Company is the manufacturer of CO2 laser systems and recommends the application of the Okklusiv ointment Vaseline® postoperatively, in order to prevent the treated tissue to the air exposition. These occlusive wound care should be maintained, until the encrustation of the laser-treated skin decreases, which usually happens 7-14 days postoperatively.
The Bepanthen® Wund- und Heilsalbe (Bayer) could be a possible alternative to Vaseline® as postoperative care. Bepanthen® Wund- und Heilsalbe contains pro-vitamin Dexpanthenol as an active ingredient and is widely used in dermatological therapy. The product helps to stabilize the protective barrier of the skin, to reduce the skin irritation, to stimulate the skin regeneration and to promote the wound healing. The investigators examined the effect of substances containing Dexpanthenol on wound healing process applied topically, in three-dimensional (3D) dermal skin equivalents in vitro. For this purpose, many lesions with standardized diameter and depth were generated using a laser. The subsequent topical application of substances containing dexpanthenol on the wound healing models (treated with laser) for three-days led to a significantly faster wound closure compared to Vaseline-covered models (Marquardt et al., 2015). The aim of this study is to compare the effect of white Vaseline with Bepanthen® "Wund- und Heilsalbe" (both applied postoperatively) on the wound healing following fractional ablative CO2 laser treatment of photo-damaged skin in vivo.
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
NRW
-
Aachen, NRW, Germany, 52057
- University Hospital RWTH Aachen
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age ≥ 18 years
- photodamaged skin, which need to be treated with the fractional ablative CO2 laser
Exclusion Criteria:
- pregnant or lactating females
- chronic diseases such as diabetes and vascular disease with impaired wound healing
- Patients, who tend to form hypertrophic scars and keloids
- Patients, who take the isotretinoin-containing medication in the past year
- topical or systemic corticosteroid treatment
- immunocompromised patients
- Patients with the Koebner phenomenon
- People with the skin type 6
- Patients with melanoma
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Bepanthen/Vaseline
One half of the wound occuring after CO2 laser therapy of photo-damaged skin is treated with Bepanthen and the other half with Vaseline.
|
Patients with photo-damaged skin are treated with the CO2 laser to remove damaged skin layers.
After the laser treatment, the wound area will be divided into two parts with a sterile skin marker.
One area will be treated with Vaseline, and be marked "V".
Thus, it is ensured that the care product will be applied correctly to the defined area.
Postoperatively, this area of the wound will be treated with Vaseline.
In the next seven days the patient will repeat the treatment every day at home.
After the laser treatment, the wound area will be divided into two parts with a sterile skin marker.
One area will be treated with Bepanthen® Wund- und Heilsalbe, and be marked "B".
Thus, it is ensured that the care product will be applied correctly to the defined area.
Postoperatively, this area of the wound will be treated with Bepanthen® Wund- und Heilsalbe.
In the next seven days the patient will repeat the treatment every day at home.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change of the diameter of the individual lesions [initial value 1.3mm] between study visits.
Time Frame: Over 2 weeks (immediately after laser treatment and on day 1, 2, 5 and 14 after laser treatment)
|
Large clinical digital photos as well as dermatoscopic images of the skin.
|
Over 2 weeks (immediately after laser treatment and on day 1, 2, 5 and 14 after laser treatment)
|
Change of the size of the individual lesions between study visits.
Time Frame: Over 2 weeks (immediately after laser treatment and on day 1, 2, 5 and 14 after laser treatment)
|
Two-dimensional microscopic skin cut images in real time of the skin.
|
Over 2 weeks (immediately after laser treatment and on day 1, 2, 5 and 14 after laser treatment)
|
Visual changes of the wound healing between study visits.
Time Frame: Over 2 weeks (immediately after laser treatment and on day 1, 2, 5 and 14 after laser treatment)
|
The wound healing rates will be visually assessed, based on the measure of re-epithelialization.
|
Over 2 weeks (immediately after laser treatment and on day 1, 2, 5 and 14 after laser treatment)
|
Change of the wound under cosmetic aspects between study visits.
Time Frame: Over 2 weeks (immediately after laser treatment and on day 1, 2, 5 and 14 after laser treatment)
|
The cosmetic result is based on a visual analog scale (VAS) from 0 (bad) to 10 (excellent, with no visible difference of the wound to the surrounding tissue).
|
Over 2 weeks (immediately after laser treatment and on day 1, 2, 5 and 14 after laser treatment)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change of the transepidermal water loss (TEWL) between study visits.
Time Frame: Over 2 weeks (immediately after laser treatment and on day 1, 2, 5 and 14 after laser treatment)
|
TEWL is the most important parameter for the assessment of skin barrier function.
|
Over 2 weeks (immediately after laser treatment and on day 1, 2, 5 and 14 after laser treatment)
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Jens M. Baron, Prof. Dr. med., RWTH Aachen University, Department of Dermatology and Allergology
Publications and helpful links
General Publications
- Bogdan Allemann I, Kaufman J. Laser principles. Curr Probl Dermatol. 2011;42:7-23. doi: 10.1159/000328236. Epub 2011 Aug 16.
- Reinholz M, Tietze JK, Kilian K, Schaller M, Schofer H, Lehmann P, Zierhut M, Klovekorn W, Ruzicka T, Schauber J. Rosacea - S1 guideline. J Dtsch Dermatol Ges. 2013 Aug;11(8):768-80; 768-79. doi: 10.1111/ddg.12101. Epub 2013 May 6. No abstract available. English, German.
- Marquardt Y, Amann PM, Heise R, Czaja K, Steiner T, Merk HF, Skazik-Voogt C, Baron JM. Characterization of a novel standardized human three-dimensional skin wound healing model using non-sequential fractional ultrapulsed CO2 laser treatments. Lasers Surg Med. 2015 Mar;47(3):257-65. doi: 10.1002/lsm.22341. Epub 2015 Mar 15.
- Wigger-Alberti W, Kuhlmann M, Ekanayake S, Wilhelm D. Using a novel wound model to investigate the healing properties of products for superficial wounds. J Wound Care. 2009 Mar;18(3):123-28, 131. doi: 10.12968/jowc.2009.18.3.39813.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 16-011
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Photodamaged Skin
-
Universitas PadjadjaranActive, not recruitingPhotodamaged SkinIndonesia
-
Revision SkincareStephens & Associates, Inc.CompletedSkin Care | Photodamaged SkinUnited States
-
Merete HaedersdalTerminated
-
Bispebjerg HospitalTerminated
-
Goldman, Butterwick, Fitzpatrick and GroffBausch Health Americas, Inc.Active, not recruiting
-
Johns Hopkins UniversityCompletedWrinkles | Photodamaged SkinUnited States
-
Austin Institute for Clinical ResearchSkinCeuticalsNot yet recruiting
-
PfizerCompleted
-
ScitonCompletedDyschromia | Photodamaged Skin
-
Mayo ClinicRecruitingAnesthesia, Local | Photodamaged Skin | Topical and Infiltration Anesthetic ToxicityUnited States
Clinical Trials on CO2-laser
-
Assiut UniversityNot yet recruitingAtrophic Scar
-
Lumenis Be Ltd.Completed
-
Cairo UniversityNot yet recruiting
-
Marta Hemmingson-Van BeekCompleted
-
Assiut UniversityUnknown
-
Rambam Health Care CampusActive, not recruiting
-
Kaplan Medical CenterUnknown
-
Hospital Clinic of BarcelonaActive, not recruitingBreast Cancer | Genitourinary Syndrome of MenopauseSpain
-
Mahidol UniversityCompleted
-
Clinica Universidad de Navarra, Universidad de...Spanish Clinical Research Network - SCReNCompleted